SUMMARY In-vitro differences in monosodium urate (MSU) crystal dissolution in paired plasma and synovial fluid samples from patients with various arthritides were studied. Plasma was a significantly better solvent for MSU than synovial fluid (overall difference 6'3 mg/dl (0 37 mmol/l); significant at P<0 001). Attempts to correlate the solubility differentials with the principal compositional differences between the 2 fluids were only partially successful. (1) A tendency towards higher MSU solubility at higher protein levels was observed, but it was too slight to reach statistical significance. (2) Hyaluronidase treatment of synovial fluid significantly enhanced its ability to dissolve MSU (overall difference 2-2 mg/dl (0.13 mmol/l); significant at P<0.01) but not sufficiently to explain wholly the plasma-synovial fluid differential.
Monosodium urate (MSU) microcrystals in synovial fluid play a central role in current schemes of pathogenesis of the acute gouty attack.1-4 However, the reason for selective deposition of MSU in synovial fluid and other connective tissues is still poorly understood. In the present investigation we studied the amounts of MSU which can be dissolved in an in-vitro system with paired samples of plasma and synovial fluid from patients with various arthritides. Attempts were made to correlate the observed differences with the known principal compositional differences between plasma and synovial fluid, namely, those in total protein and hyaluronate.
Materials and methods
Blood and synovial fluid collected in heparinised tubes were obtained from patients at St Louis University Hospitals and Arthritis Clinic and at the office of collaborating physicians. Cells and debris were removed from synovial fluid by centrifugation at 1000 g for 20 min. Only the top two-thirds of the fluid were used. Plasma and synovial fluid samples were stored at -200C prior to use.
Monosodium represents urate levels of synovialfluid treated with buffer only (37VC), 4 hr), the right-hand column (CH) those after hyaluronidase treatment under the same conditions, prior to MSU solubility studies under standardised conditions. Corresponding hyaluronidasetreated and control sanmples are connected with a line. SI conversion: Urate mmol/l=mg/dl x 0 0595. differences, as well as their statistical significance by t test for paired samples are shown in Table 2 . The overall mean difference for all patients was significant at the 99% confidence limit. Significant differences were also found for the patients with rheumatoid arthritis and those with gout, while the difference for patients with other inflammatory arthritides was not significant. The number of osteoarthritis patients included was too small to permit meaningful statistical analysis. Since MSU solubility is specifically a problem in patients with gout, it was of interest to compare the results obtained on samples from gouty patients with those from patients with other forms of arthritis. One might have expected the solubility differential between plasma and synovial fluid to be particularly large in patients with gout. This was not found to be true. The mean solubility differential for gouty patients was lower than that found in most other diseases. Similarly, the solubility change after hyaluronidase digestion was smaller than average; in fact 2 of the 3 synovial fluids in which hyaluronidase treatment did not enhance MSU solubility were from patients with gout. The significance of these findings is not clear at present.
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